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METHODS OF TREATING OR PREVENTING
ZIKA VIRUS INFECTION
CROSS - REFERENCE TO RELATED
APPLICATIONS

[ 0001 ] This application is a continuation application of
U.S. patent application Ser. No. 16/ 176,846 , filed Oct. 31 ,
2018 , which claims the benefit of U.S. Patent Application
Ser. No. 62 / 579,495 , filed on Oct. 31 , 2017. The disclosure
of the prior applications are considered part of ( and are
incorporated by reference in) the disclosure of this applica
tion .

BACKGROUND

1. Technical Field

[ 0002 ] This document relates to methods and materials for
treating a mammal having a Zika virus (ZIKV ) infection .
For example, one or more non -nucleoside RNA polymerase
inhibitors can be administered a mammal having , or at
risk of developing , a ZIKV infection to treat the mammal.
2. Background Information
[ 0003 ] ZIKV, a mosquito -borne pathogen , was originally
isolated in Uganda in 1947 (Dick et al . , 1952 Trans. Roy.
Soc. Trop . Med . Hyg. 46 : 509-520 ) and only sporadic cases
of virus outbreaks in humans were reported in Africa and
Asia in the next six decades (Mecharles et al . , 2016 Lancet
387 : 1481 ; Munoz et al . , 2016 Semin . Reprod. Med . 34 : 273
279 ) . However, in the past ten years , it has rapidly emerged
and spread to the regions of Asia , Europe, and the Americas
(Aliota et al . , 2017 Antivir. Res. 144 : 223-246 ; Chan et al . ,
2016 J. Infect. 72 : 507-524 ; Deseda , 2017 Curr. Opin . Pedi
atr. 29 : 97-101 ; Weaver et al . , 2016 Antivir. Res. 130 : 69-80) .
Although the majority of infections in humans are asymp
tomatic , recent ZIKV infections have been linked to a
variety of congenital disorders including microcephaly and
fetal growth restriction ( Carteaux et al . , 2016 N. Engl. J.
Med . 374 : 1595-1596 .; Cauchemez et al . , 2016 Lancet 387 :
2125-2132 ; Chan et al . , 2016 J. Infect. 72 : 507-524 ; Coyne
and Lazear, 2016 Nat. Rev. Microbiol. 14 : 707-715 ; Cugola

[ 0005 ] This document provides methods and materials for

treating a mammal having, or at risk of developing , ZIKV in
its bloodstream (e.g. , ZIKV viremia ). In some cases , ZIKV
viremia can lead to a ZIKV infection . For example, one or
more non -nucleoside RNA polymerase inhibitors ( e.g. ,
3 - chloro - N -[ ({4- [4- ( 2- thienylcarbonyl)-1 -piperazinyl]
phenyl} amino )carbonothioyl] -1 -benzothiophene -2 -carbox
amide (TPB ) ) can be administered to a mammal having, or
at risk of developing, ZIKV viremia to treat the mammal. In
some cases , one or more non - nucleoside RNA polymerase
inhibitors can inhibit ZIKV replication ( e.g. , within in a cell
in a mammal). In some cases , one or more non -nucleoside
RNA polymerase inhibitors can reduce ZIKV viremia in a

mammal.

[ 0006 ] As demonstrated herein , TPB inhibited ZIKV rep
lication at sub -micromolar concentrations ( e.g. , the half
maximal inhibitory concentration ( IC50 ) and the cytotoxicity
concentration ( CC50 ) of TPB in Vero cells were 94 nM and
19.4 uM , respectively, yielding a high selective index 50
( SI50 ) of 206 ) . Without being bound by theory, molecular
docking analysis suggested that TPB binds to the catalytic
active site of the ZIKV RNA - dependent RNA -polymerase
( RdRp ) and therefore likely blocks the viral RNA synthesis
by an allosteric effect. Also as demonstrated herein , TPB
reduced ZIKV viremia significantly in immunocompetent
mice . The ability to inhibit ZIKV replication can reduce
ZIKV viremia providing a unique and unrealized opportu
nity to treat and / or prevent ZIKV infections. For example,
TPB can be used to treat and /or prevent ZIKV infections.
[ 0007] In general, one aspect of this document features
methods for treating mammals having a ZIKV infection. The

methods can include, or consist essentially of , administering
to a composition including a non - nucleoside RNA poly
merase inhibitor to a mammal having a ZIKV infection to

treat the mammal. The mammal can be a human . The

Med . 374 : 951-958 ) as well as Guillain -Barre syndrome in
adults (Avelino -Silva and Martin , 2016 Lancet 387 : 2599 ;
Nascimento et al . , 2017 Neurology 88 : 2330-2332 ; and Parra
et al . , 2016 N. Engl. J. Med . 375 : 1513-1523 ) . These severe
consequences and the large - scale spreading of the virus have
imposed a significant threat to human health worldwide
( Fauci and Morens, 2016 N. Engl. J. Med . 374 : 601-604 ;
Gulland, 2016 BMJ 352 : 1657 ; Roos , 2016 J. Neurol.
73 : 1395-1396 ) . So far, no vaccine or drug for preventing or

non - nucleoside RNA polymerase inhibitor can bind to a
catalytic active site of an RdRp of a ZIKV to inhibit ZIKV
replication. The non - nucleoside RNA polymerase inhibitor
can be TPB . The non - nucleoside RNA polymerase inhibitor
can have an IC50 of from about 10 nM to about 200 nM . The
non -nucleoside RNA polymerase inhibitor can have a CC50
of from about 15 uM to about 25 uM . The non - nucleoside
RNA polymerase inhibitor can have a Slso of about 206. The
administering step can be performed prior to the mammal
being infected with the ZIKV or after the mammal being
infected with the ZIKV. The administering step can be
performed prior to the mammal being infected with the
ZIKV and after the mammal being infected with the ZIKV .
The non - nucleoside RNA polymerase inhibitor can be
administered intraperitoneally, intravenously, intramuscu
larly, or subcutaneously.
[ 0008 ] In another aspect , this document features methods
for method of preventing microcephaly in a fetus . The

Infect. Dis . 2 : 170-172 ) . Therefore, it is urgent to develop
countermeasures against this viral epidemic (Rather et al . ,

pregnant mammal has a ZIKV infection . The mammal can

et al . , 2016 Nature 534 : 267-271 ; Lazear and Diamond, 2016

J. Virol. 90 : 4864-4875 ; Miner and Diamond, 2017 Cell Host

Microbe 21 : 134-142 ; and Mlakar et al . , 2016 N. Engl. J.

treating this viral disease is available ( Shan et al . , 2016 Adv.

2017 Front. Microbiol. 8 : 305 ; Salam et al . , 2017 Ann .
Intern. Med . 166 : 725-732 ) .
SUMMARY

[ 0004 ] ZIKV has become a major human health concern
globally due to its association with congenital abnormalities
and neurological diseases .

methods can include , or consist essentially of, administering
a composition including a non - nucleoside RNA polymerase
inhibitor to a mammal pregnant with a fetus, where the

be a human . The non -nucleoside RNA polymerase inhibitor
can bind to a catalytic active site of an RdRp of a ZIKV to

inhibit ZIKV replication. The non - nucleoside RNA poly

merase inhibitor can be TPB . The non -nucleoside RNA

polymerase inhibitor can have an IC50 of from about 10 nM
to about 200 nM . The non - nucleoside RNA polymerase
inhibitor can have a CC 50 of from about 15 uM to about 25
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uM . The non -nucleoside RNA polymerase inhibitor can
have a SI5 , of about 206. The non -nucleoside RNA poly
merase inhibitor can be administered intraperitoneally, intra
venously , intramuscularly, or subcutaneously.
[ 0009 ] In another aspect , this document features methods
for treating adult mammals having Guillain -Barre syn
drome. The methods can include, or consist essentially of,
administering a composition including a non - nucleoside
RNA polymerase inhibitor to a mammal having a ZIKV
infection and having Guillain -Barre syndrome to treat the
mammal. The mammal can be a human . The non -nucleoside
RNA polymerase inhibitor can bind to a catalytic active site
of an RdRp of a ZIKV to inhibit ZIKV replication . The
non - nucleoside RNA polymerase inhibitor can be TPB . The
non -nucleoside RNA polymerase inhibitor can have an IC50
of from about 10 nM to about 200 nM . The non - nucleoside
RNA polymerase inhibitor can have a CC50 of from about 15
uM to about 25 ?M . The non - nucleoside RNA polymerase
inhibitor can have a SI50 of about 206. The non -nucleoside
RNA polymerase inhibitor can be administered intraperito
neally , intravenously, intramuscularly, or subcutaneously.
[ 0010 ] In another aspect , this document features compo
sitions for reducing ZIKV viremia within a mammal. The
compositions include a non -nucleoside RNA polymerase
inhibitor. The non -nucleoside RNA polymerase inhibitor can
be TPB . The non -nucleoside RNA polymerase inhibitor can
bind to a catalytic active site of an an RdRp of a ZIKV. The
non -nucleoside RNA polymerase inhibitor can have an IC50
of from about 10 nM to about 200 nM . The non - nucleoside
RNA polymerase inhibitor can have a CC50 of from about 15
uM to about 25 uM . The non -nucleoside RNA polymerase
inhibitor can have a S150 of about 206. The composition also
can include a pharmaceutically acceptable carrier .
[ 0011 ] Unless otherwise defined , all technical and scien
tific terms used herein have the same meaning as commonly
understood by one of ordinary skill in the art to which this
invention pertains. Although methods and materials similar
or equivalent to those described herein can be used to
practice the invention , suitable methods and materials are
described below . All publications , patent applications, pat
ents, and other references mentioned herein are incorporated
by reference in their entirety . In case of conflict, the present
specification, including definitions, will control. In addition ,
the materials, methods, and examples are illustrative only
and not intended to be limiting.
[ 0012 ] The details of one or more embodiments of the
invention are set forth in the accompanying drawings and
the description below . Other features, objects, and advan
tages of the invention will be apparent from the description
and drawings, and from the claims .

DESCRIPTION OF THE DRAWINGS

[ 0013 ] FIGS . 1A - 1D show a structure - based screening of

inhibitors of ZIKV targeting the viral RNA - dependent
RNA -polymerase (RdRp ). (FIG . 1A) Structure of ZIKV
RdRp generated by homology modeling . The three subdo
mains are colored individually, Fingers ( cyan ), Thumb
(blue ) and Palm ( red ). The catalytic active site and the
priming loop are labeled . Docking of TPB on the active site
of RdRp and the contacts with the two aspartic residues
( D535 and D665 ) along with the three hydrogen bonds are
indicated . ( FIG . 1B ) The chemical structure of TPB (mo
lecular weight of 541.108 ) . ( FIG . 1C ) A larger view of the
boxed area in A is shown for clarity. ( FIG . 1D ) The space

filing model of the boxed area in A is shown along with the
bound TPB . TPB binding at the palm subdomain is shown.

[ 0014 ] FIGS . 2A - 2B show inhibition of ZIKV replication
by the top 10 lead compounds. ( FIG . 2A) Viral genome
copies in the supernatants of cells infected with PRVABC59
virus in the presence of 1 um concentration of the ten
compounds (cl - c10 ) or with vehicle ( DMSO ) alone for 72
hours . The data are expressed as % of DMSO - treated
control. The experiment was done in triplicate and bars

represent : SEM . ( FIG . 2B ) Infectious virus titers in the
supernatant of cells infected with the virus and incubated

with 1 uM concentration of the compounds or with vehicle
( DMSO ) alone for 96 hours .
[ 0015 ] FIGS . 3A - 3C show validation of the antiviral effect
of TPB in the uM range. (FIG . 3A) Cells infected with
PRVABC59 virus were incubated in the presence of various
concentrations of TPB for 96 hours. Culture supernatants
were titrated for viral genome copies ( FIG . 3A) and infec
tious virus (FIG . 3B ) . Data are from three independent
experiments with error bars showing + SEM . Statistical
analysis was performed using unpaired two - tailed Student's
t - test to determine significance of difference .
p = 0.001 .
(FIG . 3C ) Western blot analysis of E protein expression in
virus - infected cells in the presence of various concentrations
of TPB . Relative mobility of molecular mass markers are
shown on the left .
[ 0016 ] FIGS . 4A - 4C shows TPB inhibition of ZIKV is
strain and cell- type independent. ( FIG . 4A) Inhibition of
MR766 virus by TPB . The experiments were conducted as
in FIG . 3B and data from three independent experiments are
presented with error bars representing SEM . PRVABC59
virus growth in HTR - 8 ( FIG . 4B ) and NTERRA ( FIG . 4C )
cell lines in the presence of TPB . Data from three indepen
dent experiments are presented with error bars showing
SEM . Statistical analysis was performed using unpaired
two - tailed Student's t - test to determine significance of dif
ference. ****
** , p < 0.001 .
[ 0017] FIGS . 5A - 5B show IC50 and CC50 of TBP. (FIG .
5A) Vero cells in triplicate were infected with PRVABC59
virus and incubated with various concentrations of TPB as
shown . Infectious virus titers in the supernatants of the cells
at 96 hours post- infection were determined by plaque assay
and virus yield was expressed as % of TPB - untreated
control. Non - linear regression analysis was employed to
determine the IC50 . (FIG . 5B ) Vero cells in triplicate were
treated with TPB at various concentrations for four days and
cell viability was measured based on ATP assay . The lumi
nescence signals were measured at 420 nm using a
Microplate Luminometer. Non -linear regression analysis of
the data was employed to determine the CC50 .
[ 0018 ] FIG . 6 shows a comparison of TPB inhibitory
activity with mycophenolic acid (MPA ) and Ivermectin
(IVM) . Vero cells were infected with PRVABC59 virus and
incubated with TPB ( 1 uM) , MPA ( 1 uM) and IVM ( 10 uM) .
Culture supernatants were collected at 96 hours post -infec
tion and assayed for infectious virus. Data presented are
from three independent experiments with error bars showing
SEM . Statistical analysis was performed using unpaired

two -tailed Student's t-test to determine significance of dif
ference . *** p < 0.01 ; **** p < 0.001 .

[ 0019 ] FIGS . 7A - 7D shows inhibitory efficacy of TPB in

mice . ( FIG . 7A) Pharmacokinetics (PK) analysis of TPB in
mice using two different doses as shown . ( FIG . 7B ) Genome
copies at various days post- infection in the plasma of
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individual mice treated without ( continuous lines ) or with
( discontinuous lines ) TPB . (FIG . 7C ) Data from the mice
groups in panel B. Error bars show ESEM . Statistical

analysis was performed using unpaired two -tailed Student's

t -test to determine significance of difference. **** ps0.001 .
( FIG . 7D ) TPB mean concentrations in mice plasma at
various days post - infection. Error bars show + SEM .

[ 0020 ] FIG . 8 shows model of superimposed structures of
ZIKV RdRp. Cyan, RdRp structure derived from homology
modeling ; yellow, crystal structure of RdRp ( PDB : 5WZ3 ) .
Various domains are identified .
[ 0021 ] FIGS . 9A - 9B shows models of an alignment of
compounds within the target site of the ZIKV RdRp ( FIG .
9A) and an enlarged view of the positioning of the com
pounds (FIG . 9B ) in the target site of the RdRp .
[ 0022 ] FIG . 10 contains exemplary non - nucleoside RNA
polymerase inhibitors.
DETAILED DESCRIPTION

[ 0023 ] This document provides methods and materials for
viremia (e.g. , a ZIKV infection ). In some cases , this docu
ment provides compositions ( e.g. , pharmaceutical composi
treating a mammal having, or at risk of developing ZIKV

tions such as vaccines ) including one or more non -nucleo
side RNA polymerase inhibitors ( e.g. , TPB ) . In some cases ,
this document provides methods for using one or more
non -nucleoside RNA polymerase inhibitors provided herein
to treat a mammal having, or at risk of having, a ZIKV
infection . For example, one or more non - nucleoside RNA
polymerase inhibitors can be administered to a mammal

( e.g. , a human ) having, or at risk of developing, a ZIKV

infection to treat the mammal. In some cases , one or more

non -nucleoside RNA polymerase inhibitors can inhibit
ZIKV replication (e.g. , within in a cell in a mammal ). In
some cases , one or more non -nucleoside RNA polymerase

inhibitors can reduce ZIKV viremia in a mammal. One or

more non - nucleoside RNA polymerase inhibitors can be
administered to a mammal to protect the mammal from a
ZIKV infection ( e.g. , prior to exposure to a ZIKV ) and / or to
treat the mammal (e.g. , after exposure to a ZIKV) .
[ 0024 ] Any appropriate mammal ( e.g. , a mammal having,

or at risk of developing, ZIKV viremia ) can be treated as
described herein . In some cases , a mammal can have, or can
be at risk of developing, a ZIKV infection . In some cases , a
mammal can carry ZIKV without developing ZIKV infec
tion . Examples of mammals that can be treated as described
herein ( e.g. , by administering one or more non - nucleoside
RNA polymerase inhibitors such as TPB to the mammal )
include , without limitation, humans, non -human primates
( e.g. , monkeys ), dogs , cats, horses, cows , pigs , sheep , mice ,
rats, horses , cows , carabaos ( water buffaloes ), goats , ducks,
and bats . For example, a human having, or at risk of

developing, ZIKV viremia can be treated by administering
one or more non -nucleoside RNA polymerase inhibitors

( e.g. , TPB ) to that human . In some cases , a mammal can be
a pregnant mammal (e.g. , pregnant human ). When a mam
mal is a pregnant human , the pregnant human can be in any
stage of pregnancy ( e.g. , first trimester, second trimester, or
third trimester).
[ 0025 ] When treating a mammal (e.g. , a human ) having, or

at risk of developing, ZIKV viremia ( e.g. , a ZIKV infection )
as described herein (e.g. , by administering one or more

non -nucleoside RNA polymerase inhibitors such as TPB to
the mammal), the mammal can be any appropriate age . In

some cases , a mammal can be an adult. For example , when
a mammal is a human , an adult human can be about 18 years
of age or older (e.g. , about 20 years of age , about 30 years
of age , about 40 years of age , about 50 years of age , about
60 years of age , about 65 years of age , about 70 years of age ,
or about 75 years of age or older ). For example, when a
mammal is a human, an adult human can be from about 18
years of age to about 80 years of age ( e.g. , from about 18
years of age to about 60 years of age , from about 18 years
of age to about 40 years of age, from about 25 years of age
to about 80 years of age , from about 40 years of age to about
80 years of age , from about 60 years of age to about 80 years
of age , from about 20 years of age to about 60 years of age ,
or from about 30 years of age to about 50 years of age ) . In
some cases , a mammal can be a juvenile. For example, when
a mammal is a human , a juvenile human can be no more than
about 18 years old . For example, a human adolescents can
be from about 1 year of age to about 18 years of age ( e.g. ,
from about 1 year of age to about 15 years of age , from about
1 year of age to about 10 years of age , from about 1 year of
age to about 5 years of age , from about 5 years of age to
about 18 years of age , from about 10 years of age to about
18 years of age , or from about 5 years of age to about 15
years of age ) . In some cases , a mammal can be a newborn .
For example, when a mammal is a human , a newborn human
from about birth to about 1 year of age . In some cases , a
mammal can be a fetus. For example, when a mammal is a
human , a fetus can be in utero ( e.g. , being carried by a
human pregnant with the fetus ).
[ 0026 ] When treating a mammal (e.g. , a human ) having, or
at risk of developing , ZIKV viremia ( e.g. , a ZIKV infection )
as described herein (e.g. , by administering one or more
non - nucleoside RNA polymerase inhibitors such as TPB to
the mammal ), the ZIKV can be any type of ZIKV . A ZIKV
can be from any lineage of ZIKV . A ZIKV can be from any
clade of ZIKV. A ZIKV can be any strain of ZIKV. In some
cases , a ZIKV can be a latent ZIKV . In some cases , a ZIKV
can be an infectious ZIKV. Examples of ZIKVs include ,
without limitation , East African ZIKV, West African ZIKV,
Asian ZIKV, and South American ZIKV.

[ 0027] In some cases , methods described herein can
include identifying a mammal ( e.g. , a human ) as having a
ZIKV infection . Any appropriate method can be used to
identify a mammal having a ZIKV infection . For example,
thepresence of a ZIKV in a sample obtained from a mammal
can be detected in a sample obtained from a mammal, where
the presence of a ZIKV can indicate that the mammal has a
ZIKV infection. In some cases , the presence of a ZIKV
genome, or a portion thereof, in a sample obtained from a
mammal can be used to identify that mammal (e.g. , a
human ) as having a ZIKV infection . In some cases , the

presence of one or more ZIKV polypeptides in a sample
obtained from a mammal can be used to identify that

mammal (e.g. , a human ) as having a ZIKV infection . Any
appropriate sample can be assessed to detect the presence of
a ZIKV genome, or a portion thereof, and / or the presence of
one or more ZIKV polypeptides . For example, biological
samples such as fluid samples (e.g. , blood (e.g. , whole
blood , plasma , and serum ), urine, breast milk , saliva , amni
otic fluid , cerebral spinal fluid, or semen ) or tissue samples
( e.g. , placenta tissue samples ) can be obtained from a
mammal and assessed for the presence the presence of a
ZIKV genome , or a portion thereof, and / or the presence of
one or more ZIKV polypeptides. Any appropriate method

Oct. 8 , 2020

US 2020/0316059 A1
4

can be used to detect the presence the presence of a ZIKV
genome, or a portion thereof. For example, polymerase
chain reaction ( PCR) techniques ), sequencing techniques,
and /or Southern blotting can be used to detect the presence
of a ZIKV genome, or a portion thereof, in a sample obtained
from a mammal. Any appropriate method can be used to
detect the presence the presence of one or more ZIKV
polypeptides . For example, western blotting techniques,

enzyme- linked immunosorbent assays ( ELISAs ) , and / or
more ZIKV polypeptides in a sample obtained from a

real - time PCR can be used to detect the presence of one or
mammal.

[ 0028 ] In some cases , methods described herein can
risk of developing ZIKV viremia (e.g. , a ZIKV infection ).

include identifying a mammal (e.g. , a human ) as being at

For example, a mammal undergoing, or scheduled to
undergo , exposure to one or more mammals having ZIKV
viremia can be at risk of developing ZIKV viremia . In some
cases , a mammal having physical contact (e.g. , sexual
contact) with one or more mammals having ZIKV viremia
can be at risk of developing ZIKV viremia ( e.g. , a ZIKV
infection ). In some cases , a mammal living in or moving to
an area where one or more mammals having ZIKV viremia
are present can be at risk of developing ZIKV viremia ( e.g. ,
a ZIKV infection ). In some cases , a mammal scheduled to
travel to an area where one or more mammals having ZIKV
viremia are present can be at risk of developing ZIKV
viremia (e.g. , a ZIKV infection ). In some cases , a mammal
that has been bitten , or is at risk of being bitten by an animal
that carries a ZIKV virus (e.g. , a mosquito ) can be at risk of
developing ZIKV viremia ( e.g. , a ZIKV infection ). In some
cases , a fetus within a pregnant mammal with ZIKV viremia
can be at risk of developing ZIKV viremia ( e.g. , a ZIKV
infection )
[ 0029 ] A mammal ( e.g. , a human ) identified as having , or
as being at risk of developing , ZIKV viremia (e.g. , a ZIKV
infection ), can be administered, or instructed to self -admin
ister, one or more non - nucleoside RNA polymerase inhibi
tors . For example, one or more non -nucleoside RNA poly
merase inhibitors can be administered to a mammal in need
thereof ( e.g. , a mammal having, or at risk of developing,
ZIKV viremia ). A non - nucleoside RNA polymerase inhibi
tor can be any appropriate non -nucleoside RNA polymerase
inhibitor. A non - nucleoside RNA polymerase inhibitor can
be a chemically synthesized non - nucleoside RNA poly
merase inhibitor. A non -nucleoside RNA polymerase inhibi
tor can be a commercially obtained non -nucleoside RNA
polymerase inhibitor. Examples of non - nucleoside RNA
polymerase inhibitors that can be used as described herein
( e.g. , to treat a mammal having, or at risk of developing,
ZIKV viremia ) include, without limitation, non - nucleoside
RNA polymerase inhibitors shown in FIG . 10 ( e.g. , TPB ,
C1 , C2 , C3 , C4 , C5 , C6 , C7 , C8 , C9 , and C10) . In some
cases , a non - nucleoside RNA polymerase inhibitor can be
TPB . In cases where a non -nucleoside RNA polymerase
inhibitor is TPB , the TPB can be a derivative of TPB . As
used herein , a derivative of a non -nucleoside RNA poly
merase can be any structurally derived compound that
maintains the ability to inhibit a non - nucleoside RNA poly
merase . For example, a mammal having, or at risk of
developing, ZIKV viremia can be administered or can
self - administer TPB .
[ 0030 ] A non -nucleoside RNA polymerase inhibitor ( e.g. ,
TPB ) can inhibit ZIKV replication. In some cases , a non

nucleoside RNA polymerase inhibitor can inhibit transcrip
tion of a ZIKV coding sequence (e.g. , coding sequence
encoding a ZIKV polymerase such as the RdRp polymerase
gene ). In some cases , a non -nucleoside RNA polymerase
inhibitor can inhibit function of a ZIKV polypeptide (e.g. , a
ZIKV polymerase such as the RdRp polymerase ). For
example, when a non -nucleoside RNA polymerase inhibitor
is TPB , the TPB can inhibit function of the RdRp poly
merase . In some cases , TPB can target (e.g. , bind to ) a
catalytic active site of the RdRp polymerase to inhibit ZIKV
replication .
[ 0031 ] A non -nucleoside RNA polymerase inhibitor can
be a potent inhibitor ( e.g. , a potent ZIKV inhibitor ). For
example, when a non -nucleoside RNA polymerase inhibitor
is TPB , the TPB can inhibit a ZIKV ( e.g. , inhibit ZIKV
replication ) at sub -micromolar concentrations . In some
cases , the inhibitory concentration 50 (IC50 ) of TPB can
from about 10 nM to about 200 nM (e.g. , from about 10 nM
about 10 nM to about 125 nM , from about 10 nM to about

to about 175 nM , from about 10 nM to about 150 nM , from
100 nM , from about 10 nM to about 75 nM , from about 10
nM to about 60 nM , from about 10 nM to about 50 nM , from

about 10 nM to about 40 nM , from about 10 nM to about 30
nM , from about 10 nM to about 20 nM , from about 25 nM

to about 200 nM , from about 50 nM to about 200 nM , from
about 70 nM to about 200 nM , from about 90 nM to about
200 nM , from about 100 nM to about 200 nM , from about
125 nM to about 200 nM , from about 150 nM to about 200

nM , from about 175 nM to about 200 nM , from about 25 nM

to about 175 nM , from about 50 nM to about 150 nM , from

about 75 nM to about 125 nM , from about 50 nM to about
100 nM , from about 100 nM to about 150 nM , from about
30 nM to about 80 nM , from about 50 nM to about 70 nM ,

or from about 85 nM to about 95 nM) . For example, the IC50

of TPB can be about 94 nM .

[ 0032 ] A non -nucleoside RNA polymerase inhibitor can
have low toxicity (e.g. , cellular toxicity or cytotoxicity ) . For
example, when a non -nucleoside RNA polymerase inhibitor
is TPB , the TPB can have sub -micromolar cytotoxicity
concentrations. In some cases , the cellular cytotoxicity con

centration 50 (CC50 ) of TPB can be from about 15 uM to
about 25 uM . For example, the CC50 of TPB can be about
19.4 uM .
[ 0033 ] A non -nucleoside RNA polymerase inhibitor can
have high selectivity (e.g. , can be selective for a ZIKV ). A
selective index 50 ( SI50 ) can be determined using the
formula CC50/ IC50 . For example, when a non - nucleoside
RNA polymerase inhibitor is TPB , the TPB can have a high
SI50 . In some cases , the S150 of TPB can be from about 150
to about 250. For example, the S150 of TPB can be about 206 .
[ 0034 ] When treating a mammal having, or at risk of
developing, ZIKV viremia ( e.g. , a ZIKV infection ), one or
more non -nucleoside RNA polymerase inhibitors ( e.g. ,
TPB ) can be administered to the mammal at any appropriate
time . For example, when a mammal has ZIKV viremia, one
or more non - nucleoside RNA polymerase inhibitors can be
administered before , during ( e.g. , concurrent with ), and / or
after one or more symptoms of a ZIKV infection are
producing or showing ( e.g. , after a ZIKV infection has
developed ). In some cases , when a mammal has ZIKV
viremia, one or more non -nucleoside RNA polymerase
inhibitors can be administered before one or more symptoms
of a ZIKV infection producing or showing no symptoms
(e.g. , when the mammal is asymptomatic and /or prior to a
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ZIKV infection developing ) . For example , when a mammal
at risk of developing ZIKV viremia ( e.g. , a ZIKV infection )
is undergoing, or scheduled to undergo, exposure to one or
more mammals having ZIKV viremia ( e.g. , a ZIKV infec
tion ), one or more non - nucleoside RNA polymerase inhibi
tors can be administered before , during (e.g. , concurrent
with ), and /or after the exposure .
[ 0035 ] One or more non - nucleoside RNA polymerase
inhibitors (e.g. , TPB ) can be administered to a mammal in
need thereof (e.g. , a mammal having , or at risk of develop
ing , ZIKV viremia ) by any appropriate route . Administration
can be local or systemic. Examples of routes of administra
tion include, without limitation , intraperitoneal, intravenous ,

intramuscular, subcutaneous , oral, intranasal, inhalation,
transdermal, and parenteral administration . For example,
one or more non -nucleoside RNA polymerase inhibitors can
be administered intraperitoneally to a mammal (e.g. , a
human ).
[ 0036 ] When treating a mammal having, or at risk of
developing, ZIKV viremia (e.g. , a ZIKV infection ), the
treatment can include the administration of a therapeutically
effective amount of one or more non -nucleoside RNA
inhibitors . The terms " effective amount ” and “ therapeuti
cally effective amount ” refer to that amount of one or more
non -nucleoside RNA inhibitors sufficient to result in a

therapeutic effect. For example, a therapeutic effect of
treating a mammal having, or at risk of developing, ZIKV
viremia can include , without limitation , inhibition of ZIKV
replication , reduction or elimination of ZIKV viremia, and /
or amelioration (e.g. , reduction or elimination ) of one or
more symptoms of a ZIKV infection .
[ 0037] In some cases , treating a mammal having, or at risk
of developing, ZIKV viremia ( e.g. , a ZIKV infection ) as
described herein (e.g. , by administering one or more non
nucleoside RNA polymerase inhibitors such as TPB to the
mammal) can be effective to inhibit ZIKV replication. For
example, administering one or more non -nucleoside RNA
polymerase inhibitors to a mammal can be effective to
inhibit ZIKV replication within in one or more cells in that
mammal. Any appropriate method can be used to determine
whether or not ZIKV replication has been inhibited . For
example , quantitative RT - PCR (RT - qPCR ) and / or ELISAS
can be used to determine whether or not ZIKV replication
has been inhibited .
[ 0038 ] In some cases , treating a mammal having, or at risk
of developing, ZIKV viremia ( e.g. , a ZIKV infection ) as
described herein (e.g. , by administering one or more non

nucleoside RNA polymerase inhibitors such as TPB to the

mammal) can be effective to reduce or eliminate ZIKV
viremia . For example, administering one or more non
nucleoside RNA polymerase inhibitors to a mammal can be
effective to reduce ZIKV viremia within that mammal.

[ 0039 ] In some cases , administering one or more non

nucleoside RNA polymerase inhibitors to a mammal having
ZIKV viremia can be effective to reduce ZIKV viremia by
from about 40 - fold to about 1000 - fold ( e.g. , from about
50 - fold to about 1000 -fold , from about 80 - fold to about
1000 -fold , from about 100 - fold to about 1000 - fold , from

about 300 - fold to about 1000 - fold , from about 500 - fold to

about 1000 - fold , from about 700 - fold to about 1000 - fold ,
from about 800 - fold to about 1000 - fold , from about 900

fold to about 1000 - fold , from about 40 - fold to about 900
fold, from about 40 - fold to about 700 - fold , from about
40 - fold to about 500 - fold , from about 40 - fold to about

200 - fold, from about 40 - fold to about 100 - fold , from about

50 - fold to about 900 - fold , from about 200 - fold to about
800 - fold , from about 500 - fold to about 700 - fold , from about

100 - fold to about 400 -fold , from about 300 - fold to about
600 - fold, from about 400 - fold to about 700 - fold, from about
500 - fold to about 800 - fold , or from about 600 - fold to about

900 - fold ) within that mammal. In some cases , administering
one or more non -nucleoside RNA polymerase inhibitors to
a mammal having ZIKV viremia can be effective to reduce
a ZIKV genome copy number within a mammal. In some
cases , administering one or more non - nucleoside RNA
polymerase inhibitors to a mammal having ZIKV viremia

can be effective to reduce PFU of ZIKV virus within a

mammal .

[ 0040 ] Any appropriate method can be used to determine

the presence , absence , or amount of ZIKV in a mammal. For
example, RT- qPCR can be used to determine the presence ,
absence , or amount of ZIKV in a mammal.

[ 0041 ] In some cases , treating a mammal having, or at risk
of developing , ZIKV viremia ( e.g. , a ZIKV infection ) as
described herein (e.g. , by administering one or more non
nucleoside RNA polymerase inhibitors such as TPB to the
mammal) can be effective to reduce the severity of the ZIKV

infection and /or to reduce or eliminate one or more symp
toms of the ZIKV infection . In some cases , when a mammal

is a pregnant mammal (e.g. , a pregnant human ), one or more

symptoms can affect the mammal's fetus ( e.g. , in utero )
and / or can affect the mammal's child ( e.g. , after birth such
as a newborn child) . Examples of symptoms of a ZIKV
infection can include, without limitation , fever, rash ( e.g. ,
maculopapular rash ), muscle pain , joint pain , conjunctivitis,
vomiting, headache , and congenital Zika syndrome ( e.g. ,
including, but not limited to , microcephaly, decreased brain
tissue , damage to the back of the eye such as scarring and /or

pigment changes, joints with limited range of motion such as
clubfoot, and / or too much muscle tone restricting body

movement soon after birth ). In some cases , a symptom of
ZIKV infection can be as described elsewhere ( see , e.g. ,
www.cdc.gov/zika/symptoms/index.html). For example ,

treating a pregnant mammal (e.g. , a pregnant human ), hav
ing , or at risk of developing, ZIKV viremia ( e.g. , a ZIKV
infection) as described herein (e.g. , by administering one or
more non - nucleoside RNA polymerase inhibitors such as
TPB to the mammal) can be effective to reduce or eliminate
microcephaly in the mammal's fetus and / or the mammal's
child ( e.g. , after birth ).
[ 0042 ] In some cases , one or more non -nucleoside RNA
polymerase inhibitors (e.g. , TPB ) can be administered to a
mammal having , or at risk of developing, ZIKV viremia
(e.g. , a ZIKV infection ) in the absence of any carriers ( e.g. ,

additives, fillers , vehicles, and / or diluents ).

[ 0043 ] In some cases , one or more non - nucleoside RNA
polymerase inhibitors (e.g. , TPB ) can be formulated into a
composition ( e.g. , a pharmaceutically acceptable composi
tion) for administration to a mammal having, or at risk of
developing, ZIKV viremia (e.g. , a ZIKV infection ). For
example , one or more non - nucleoside RNA polymerase
inhibitors can be formulated together with one or more
pharmaceutically acceptable carriers ( e.g. , additives, fillers,
vehicles, and / or diluents ). In some cases , pharmaceutically
acceptable carrier can be non -naturally occurring. Pharma
ceutically acceptable carriers that can be used in a pharma
ceutical composition described herein include, without limi
tation , dextrose , methanol, dimethyl sulfoxide (DMSO ) , ion
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exchangers, alumina , aluminum stearate , lecithin , serum

proteins, such as human serum albumin , buffer substances
such as phosphates, glycine, sorbic acid, potassium sorbate ,
partial glyceride mixtures of saturated vegetable fatty acids ,
water, salts or electrolytes, such as protamine sulfate, diso
dium hydrogen phosphate , potassium hydrogen phosphate ,
sodium chloride, zinc salts , colloidal silica , magnesium
trisilicate , polyvinyl pyrrolidone , cellulose -based sub
stances, polyethylene glycol , sodium carboxymethylcellu
lose , polyacrylates, waxes, polyethylene -polyoxypropylene

block polymers, and wool fat.
[ 0044 ] In some cases , a composition including one or
more non - nucleoside RNA polymerase inhibitors ( e.g. ,
TPB ) to be administered to a mammal ( e.g. , a human ) in
need thereof (e.g. , a mammal having , or at risk of develop
ing , ZIKV viremia ) can include one or more non -nucleoside
RNA polymerase inhibitors as the sole active ingredient. For
example, TPB can be administered to a mammal having , or
at risk of developing, ZIKV viremia ( e.g. , a ZIKV infection )
as the sole active ingredient used to treat the mammal.

[ 0045 ] In some cases , a composition including one or
more non -nucleoside RNA polymerase inhibitors ( e.g. ,
TPB ) to be administered to a mammal ( e.g. , a human ) in
need thereof (e.g. , a mammal having , or at risk of develop
ing , ZIKV viremia) can include one or more non - nucleoside
RNA polymerase inhibitors together with one or more
additional active ingredients ( e.g. , active ingredients that can
be used to treat a mammal having, or at risk of developing,
ZIKV viremia ). Examples of additional active ingredients

that can be used to treat a mammal having , or at risk of
developing, ZIKV viremia (e.g. , a ZIKV infection ) that can
be used to treat a ZIKV infection include , without limitation ,

anti- histamines ( e.g. , chlorphenamine), corticosteroids (e.g. ,
hydrocortisone), fever reducers ( e.g. , acetaminophen ),
immunosuppressants ( e.g. , mycophenolic acid ), and anti
parasitics ( e.g. , ivermectin ).

[ 0046] A composition including one or more non -nucleo

side RNA polymerase inhibitors (e.g. , TPB ) can be designed
for any route of administration . For example , a composition
including one or more non -nucleoside RNA polymerase

inhibitors can be designed for parenteral ( e.g. , intraperito
neal) administration . Compositions suitable for parenteral

administration include, without limitation , aqueous and non
aqueous sterile injection solutions that can contain anti
oxidants, buffers, bacteriostats, and solutes that render the

formulation isotonic with the blood of the intended recipi

ent . For example, a composition including one or more
non -nucleoside RNA polymerase inhibitors can be designed
for oral administration. Compositions suitable for oral
administration include, without limitation , liquids, tablets ,
capsules, pills , powders, gels , and granules. In some cases ,
a composition including one or more non -nucleoside RNA

polymerase inhibitors can be formulated for oral adminis
tration .

[ 0047] A composition including one or more non -nucleo
for any type of release ( e.g. , release of the one or more
non - nucleoside RNA polymerase inhibitors from the com
position) into the mammal the composition is administered
to (e.g. , a mammal having, or at risk of developing, ZIKV
viremia ). For example, a composition including one or more
non - nucleoside RNA polymerase inhibitors can be designed

side RNA polymerase inhibitors (e.g. , TPB ) can be designed

for immediate release, slow release , or extended release .

[ 0048 ] A composition including one or more non -nucleo
istered to a mammal (e.g. , a human ) in need thereof ( e.g. , a
mammal having, or at risk of developing, ZIKV viremia ) in
any appropriate dose ( s ). Effective doses can vary depending
on the level of ZIKV viremia , the risk of developing ZIKV
infection, the route of administration , the age and general
health condition of the mammal, excipient usage , the pos
sibility of co -usage with other therapeutic treatments such as
use of other agents, and the judgment of the treating phy
sician . For example, in cases where a composition includes
TPB , the composition can include from about 5 mg TPB per
kilogram (kg) body weight of the mammal being treated to
about 25 mg TPB per kg body weight of the mammal being
treated ( e.g. , from about 7 mg /kg to about 25 mg /kg, from
about 10 mg/kg to about 25 mg /kg, from about 12 mg/kg to
about 25 mg/kg, from about 15 mg /kg to about 25 mg /kg,
from about 18 mg /kg to about 25 mg/kg, from about 20
mg /kg to about 25 mg /kg, from about 22 mg/kg to about 25
mg/kg, from about 5 mg/kg to about 23 mg/kg, from about
5 mg/kg to about 20 mg/kg, from about 5 mg/kg to about 17
mg/kg, from about 5 mg/kg to about 15 mg/kg, from about
5 mg/kg to about 12 mg/kg, from about 5 mg/kg to about 10
mg/kg, from about 5 mg/kg to about 8 mg/kg, from about 8
mg /kg to about 22 mg/kg, from about 10 mg /kg to about 20
mg/kg, from about 12 mg /kg to about 17 mg/kg, from about
10 mg/kg to about 15 mg /kg, or from about 15 mg /kg to
about 20 mg /kg TPB ) . In some cases , a composition includ
ing TPB can include about 25 mg/kg TPB . For example, in
cases where a composition includes TPB , the composition
side RNA polymerase inhibitors (e.g. , TPB ) can be admin

can be effective to achieve from about 100 ng of TPB per

milliliter (mL ) plasma in the mammal being treated to about
1000 ng of TPB per mL plasma in the mammal being treated
(e.g. , a plasma concentration of from about 200 ng /mL to
about 1000 ng /mL, from about 250 ng /mL to about 1000
ng/mL, from about 275 ng /mL to about 1000 ng/mL, from
about 300 ng /mL to about 1000 ng /mL , from about 350
ng /mL to about 1000 ng /mL , from about 400 ng/mL to about
1000 ng/mL , from about 450 ng /mL to about 1000 ng /mL ,
from about 500 ng /mL to about 1000 ng/mL , from about 550
ng /mL to about 1000 ng /mL , from about 600 ng/mL to about
1000 ng/mL , from about 650 ng/mL to about 1000 ng /mL,
from about 700 ng /mL to about 1000 ng /mL , from about 750
ng/mL to about 1000 ng /mL , from about 800 ng /mL to about
1000 ng /mL , from about 850 ng/mL to about 1000 ng /mL ,
from about 900 ng /mL to about 1000 ng/mL , from about 100
ng/mL to about 900 ng /mL , from about 100 ng /mL to about
800 ng /mL , from about 100 ng /mL to about 700 ng/mL ,
from about 100 ng /mL to about 600 ng /mL , from about 100
ng /mL to about 500 ng /mL, from about 100 ng /mL to about
400 ng/mL , from about 100 ng /mL to about 300 ng /mL ,
from about 200 ng /mL to about 900 ng /mL, from about 300
ng /mL to about 800 ng /mL , from about 400 ng /mL to about
700 ng /mL , from about 500 ng /mL to about 600 ng/mL ,
from about 200 ng /mL to about 400 ng /mL , from about 400
ng/mL to about 600 ng/mL, or from about 600 ng/mL to
about 800 ng /mL TPB ) . In some cases , a composition
including TPB can achieve a plasma concentration of greater
than 500 ng /mL TPB (e.g. , a plasma concentration of about
550 ng /mL , about 600 ng /mL , about 650 ng /mL , about 700
ng /mL , about 750 ng/mL, about 800 ng /mL , about 850
ng/mL, about 900 ng /mL , or about 950 ng/mL TPB ) . An
effective amount of a composition including one or more
non -nucleoside RNA polymerase inhibitors can be any
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amount that reduces the severity and /or reduces or elimi
producing significant toxicity to the mammal. The effective
amount can remain constant or can be adjusted as a sliding
nates one or more symptom of a ZIKV infection without

scale or variable dose depending on the mammal's response

to treatment. Various factors can influence the actual effec

tive amount used for a particular application . For example,

the frequency of administration, duration of treatment, use
of multiple treatment agents, route of administration , level
of ZIKV viremia , severity of the ZIKV infection , and risk of
developing a ZIKV infection may require an increase or
decrease in the actual effective amount administered .

[ 0049 ] A composition including one or more non -nucleo

side RNA polymerase inhibitors (e.g. , TPB ) can be admin
istered to a mammal (e.g. , a human ) in need thereof ( e.g. , a
mammal having, or at risk of developing, ZIKV viremia ) in
any appropriate frequency. The frequency of administration
can be any frequency that reduces the severity of the ZIKV
infection and / or reduces or eliminates one or more symp
toms of the ZIKV infection without producing significant
toxicity to the mammal. For example, the frequency of
administration can be from about once a day to about ten
times a day, from about three times a day to about eight
times a day, or from about four times a day to about six times
a day. The frequency of administration can remain constant
or can be variable during the duration of treatment. As with
the effective amount, various factors can influence the actual
frequency of administration used for a particular application .
For example, the effective amount, duration of treatment,
use of multiple treatment agents, route of administration ,
level of ZIKV viremia , severity of the ZIKV infection, and
risk of developing a ZIKV infection may require an increase
or decrease in administration frequency.

[ 0050 ] A composition including one or more non -nucleo

include not taking aspirin and / or other non - steroidal anti

inflammatory drugs ( NSAIDS ). In some cases , a ZIKV

infection treatment can include administration of one or

more pharmacotherapies such as antibiotics ( e.g. , metron
idazole and dexamethasone ), anti -histamines (e.g. , chlo
rphenamine ), corticosteroids (e.g. , hydrocortisone ), and / or
fever reducers (e.g. , acetaminophen) . For example, a mam
mal having, or at risk of developing , ZIKV viremia ( e.g. , a
ZIKV infection ) can be administered one or more non

nucleoside RNA polymerase inhibitors ( e.g. , TPB ) and can

be administered one or more additional treatments used to

treat a ZIKV infection. In cases where a mammal having, or

at risk of developing , ZIKV viremia ( e.g. , a ZIKV infection )
is treated with one or more non -nucleoside RNA polymerase

inhibitors and is treated with one or more additional agents
used to treat a ZIKV infection, the additional treatment used

to treat a ZIKV infection can be administered at the same

time or independently. For example, when administered
independently , the one or more non - nucleoside RNA poly

merase inhibitors can be administered first, and the one or

more additional treatment used to treat a ZIKV infection can

be administered second, or vice versa .
[ 0052 ] In certain instances, a course of treatment and the

severity of one or more symptoms related to the condition
being treated ( e.g. , a ZIKV infection ) can be monitored . Any
appropriate method can be used to determine whether or not
the severity of one or more symptoms is reduced or elimi
nated . For example , the severity of a ZIKV infection can be
assessed using any appropriate methods and /or techniques ,
and can be assessed at different time points. For example,
physical examinations can be used to determine the severity
of one or more symptoms of a ZIKV infection .
[ 0053 ] In some cases , one or more non - nucleoside RNA

polymerase inhibitors (e.g. , TPB ) can be used to treat a

side RNA polymerase inhibitors (e.g. , TPB ) can be admin
istered to a mammal (e.g. , a human ) in need thereof ( e.g. , a
mammal having , or at risk of developing , ZIKV viremia ) for
any appropriate duration. An effective duration for admin
istering a composition including one or more biguanides can
be any duration that reduces the severity of the ZIKV
infection and /or reduces or eliminates one or more symp
toms of the ZIKV infection without producing significant
toxicity to the mammal. For example, the effective duration
can vary from several days to several months or years to a
lifetime. In some cases , the effective duration for the treat
ment of mammal in need thereof can range in duration from
about 2 days to about a week . Multiple factors can influence
the actual effective duration used for a particular treatment.
For example, an effective duration can vary with the fre
quency of administration , effective amount, use of multiple
treatment agents, route of administration , level of ZIKV
viremia , severity of the ZIKV infection, and risk of devel
oping a ZIKV infection .
[ 0051 ] In some cases , methods described herein also can
include administering to a mammal in need thereof (e.g. , a
mammal having, or at risk of developing , ZIKV viremia )

mammal having a disease or disorder associated with a
ZIKV infection . Examples of diseases and disorders asso
ciated with a ZIKV infection include , without limitation ,
Guillain - Barre syndrome.

having, or at risk or developing , ZIKV viremia ( e.g. , a ZIKV
infection ). The one or more additional treatments used to

non -nucleoside RNA inhibitors . For example, a kit can
include one or more non - nucleoside RNA inhibitors and one
or more pharmaceutically acceptable carriers ( e.g. , addi
tives , fillers, vehicles, and / or diluents ) for preparing and / or
administering a composition ( e.g., a vaccine composition ).
In some cases , a kit provided herein can include reagents

one or more additional treatments used to treat a mammal

treat a ZIKV infection can include any appropriate treat
getting plenty of rest . In some cases , a ZIKV infection
treatment can include drinking fluids (e.g. , to prevent dehy
dration ). In some cases , a ZIKV infection treatment can

ment. In some cases , a ZIKV infection treatment can include

[ 0054 ] In some cases , one or more non - nucleoside RNA

merase inhibitors (e.g. , TPB ) can be used to treat
mammal having, or at risk of developing, one or more
additional infections caused by a member of the Flaviviridae
family, which includes Dengue viruses, West Nile viruses,
yellow fever viruses, and Japanese encephalitis viruses.
[ 0055 ] This document also provides kits that can be used
for a variety of applications including, without limitation ,
diagnosing a mammal as having, or as being at risk of
developing, ZIKV viremia (e.g. , a ZIKV infection ); treating
a mammal having, or at risk of developing, ZIKV viremia
(e.g. , a ZIKV infection ); and / or preparing a composition
( e.g., by combining reagents ) for use in diagnosing and / or

treating a mammal having, or at risk of developing , ZIKV
viremia (e.g. , a ZIKV infection ). In some cases , a kit
provided herein can include one or more non - nucleoside
RNA inhibitors ( e.g. , TPB ) as described herein . For
example, a kit can include a composition ( e.g. , a pharma
ceutically acceptable composition) including one or more

that can be used to detect ZIKV infections. For example a kit
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provided herein can be designed as a diagnostic kit . For
example , a kit provided herein can be designed as a kit to
monitor treatment of a mammal having , or at risk of devel
oping , ZIKV viremia ( e.g. , a ZIKV infection ). For example ,
a kit provided herein can be designed to include reagents that
can be used to detect the presence of a ZIKV genome, or a
portion thereof, and / or the presence of one or more ZIKV
polypeptides in samples ( e.g. , fluid samples such as blood
and urine) obtained from a mammal . In some cases , a kit
provided herein also can include packaging. In some cases ,
a kit provided herein also can include, instructions for use .
For example, instructions for use can be provided as a
separate component within the kit and /or printed directly on
any packaging ( e.g. , packaging for the kit or packaging for
a component within the kit) .
[ 0056 ] The invention will be further described in the
following examples, which do not limit the scope of the
invention described in the claims .

EXAMPLES

Example 1 : Discovery of a Non -Nucleoside RNA
Polymerase Inhibitor for Blocking Zika Virus
Replication Through in Silico Screening
Materials and Methods

Compounds
[ 0057 ] Ten lead compounds ( Table 1 ) were purchased
from Hit2Lead Company ( ChemBridge Corporation, San
Diego , Calif . ). Each compound was dissolved in dimethyl
sulfoxide (DMSO ) to prepare stock solutions of 10 mM and
1 mM and was stored at -20 ° C. The compound 1 (cl ) used
in this research is 3 - chloro - N -[ ({ 4- [4- (2 -thienylcarbonyl)
1 -piperazinyl ]phenyl) amino ) carbonothioyl ] -1 - benzothio
phene- 2 - carboxamide (TPB ) . Based on 1H NMR and LC
MS (ELSD , DAD 200-400 nm , MSD APCI positive )
analyses by the provider, the compound is 95 % pure .
Mycophenolic acid (MPA ) and Ivermectin ( IVM) were
purchased from Sigma ( St. Louis , Mo. ) and resuspended in
DMSO to prepare stock solutions . All the compounds used

have > 95 % purity.

Docking scores of the top 10 compounds.

Molecular Weight

Score

541.108

455.52

-118.794
-118.36

4
5

525.572
516.638
476.480

-118.097
-117.319

6
7

539.618
484.618

-116.087
-115 . 23

1
2
3

8

471.592

9
10

471.574
482.443

penicillin / streptomycin ( PS ) in humidified chamber with 5 %
CO2 at 37 ° C. Zika virus strain PRVABC59 and MR766

were obtained from Barbara Johnson and Brandy Russell at
the Centers for Disease Control and Prevention , Fort Col
lins , Colo . , USA . The viruses were passaged once in Vero
cells to prepare stocks and were stored at -80 ° C. in small
aliquots. Titers of the stock viruses were determined by
plaque assay using Vero cells as described elsewhere ( see ,
e.g. , Annamalai et al . , 2017 J. Virol. 91 : e01348-17 ) .
Molecular Modeling and in Silico Screening
[ 0059 ] The ZIKV RdRp structure was modeled based on

sequence homology using Modeller 9 program (Webb and
Sali , 2014 ) . The DENV - 3 RdRp structure (PDB : 217U) was

used as the template. In silico screening was performed
using Molegro Virtual Docker (MVD ) (Molegro ApS, Aar
hus, Denmark ). The docking site was defined using a ray
tracing algorithm . This resulted in a cavity with a volume of

approximately 1034 cubic Å . A receptor grid was built

within this cavity with a resolution of 0.2 Å and a radius of
13 Å from the geometric center of the cavity in the ZIKV
RdRp model . A 100,000 compound library from Chem
Bridge (Chembridge DIVERSetTM Chemical Library,
ChemBridge Corporation, San Diego , Calif.) was used for
this virtual screening. All structural analysis were conducted
in the Discovery Studio 4.0 ( Biovia , San Diego , Calif. ).
Inhibition Assays
[ 0060 ] Vero cells were seeded in a 96 - well plate with the
density of 6000 cells per well . In the initial screening study,
the compound ( 1 uM )-virus (0.1 PFU /cell) mixture in virus
growth medium (VGM) [ DMEM containing 2 % FBS , PS ,
20 mM hydroxyethyl piperazine ethane sulfonic acid
(HEPES ) , 1 mM sodium pyruvate , and non - essential amino
acids ] was added to the cells and incubated for 72 h . In a
separate experiment conducted using 12 - well plates, the
cells were first infected with the virus at 0.1 PFU / cell and
following adsorption, the cells were washed twice in PBS

and incubated in VGM containing 1 uM concentrations of
the drugs. The cell culture media were collected at 72-96 h

TABLE 1
Compound

obtained from ATCC . The cells were grown and maintained
in Dulbecco's modified Eagle's medium ( DMEM) contain
ing 10 % heat- inactivated fetal bovine serum (FBS ) and

-118 .

-115.789
-115.724
-114.333

indicates text missing or illegible when filed

Cells and Viruses

[ 0058 ] Vero ( Cercopithecus aethiops, CCL - 81 ) , HTR - 8 /
SVneo human trophoblast ( CRL - 3271 ) , and NTERA - 2
human embryonal carcinoma ( CRL - 1973 ) cells were

post- infection and assayed for infectious virus by plaque
assay and viral genome copies by quantitative RT -PCR
(RT-qPCR ). In all subsequent studies, cells in 12 -well plates
were infected with ZIKV at MOI of 0.1 PFU / cell and

following virus adsorption for 1 h at 37 ° C., VGM contain
ing various concentrations TPB was added to the cells and
incubated as above . Clarified supernatants from the infected
cells were then used to determine infectious virus or genome
copies as above.
ATP -Based Cell Viability Assay
[ 0061 ] A modified ATP based cytopathic effect (CPE )
assay was used for this study based on the CPE method for
anti - DENV drug development described elsewhere ( see ,
e.g. , Che et al . , 2009 Int. J. Clin . Exp . Med . 2 : 363-373 ) . Vero
cells (approximately 30,000 per well ) were seeded in a black
96 - well plate for 24 hours before the experiment. Cell
monolayers were treated with various concentrations of the
drugs for 4 days at 37 ° C. The ATP concentration was
measured following manufacturer's recommendations using
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CellTiter -Glo kit from Promega (Madison, Wis .). Lumines
cence was recorded using a Veritas Microplate Luminometer
at 420 nm . The 50 % cytotoxic concentration ( CC50 ) was
calculated by a non - linear regression analysis of the dose
response curves.

Quantitative Real Time RT -PCR
[ 0062 ] ZIKV viral RNA was detected using RT -qPCR on
a C100 Thermal Cycler and the CFX96 Real - Time system
( Bio -Rad ). Viral RNA ( VRNA ) was extracted from culture
supernatant using a Q1Aamp Viral RNA Mini kit ( Qiagen )
and TaqMan Fast Virus 1 - Step Master Mix ( Life technolo
gies ) . ZIKV primers and probe ( ZIKF : CCGCTGC

CCAACACAAG ( SEQ ID NO : 1 ) ; ZIK - R : CCACTAACGT
TCTTTTGCAGACAT ( SEQ ID NO : 2 ) ; PCR Probe: ZIK - P :
AGCCTACCTTGACAAGCAATCAGACACTCAA ( SEQ
ID NO : 3 ) ) were used for quantitative RT -PCR ( RT -qPCR )
with the following parameters: 50 ° C. 30 min , 95 ° C. 5 min ,
( 95 ° C. 30 S , 58 ° C. 1 min) x40 cycles . RNA standard
concentrations were determined based on the back calcula
tion with OD values and molecular weights and were
generated through serial dilution with R2 >0.95 .
Pharmacokinetic ( PK ) Study Design
[ 0063 ] For PK studies , groups of Balb /C mice ( n = 3 ) were

injected intraperitoneally with doses of 5 mg/kg or 25 mg/kg
of body weight of TPB in 5 % dextrose, plasma was collected
from the animals at various times post- injection and stored
at -80 ° C. until analysis by LC - MS /MS for TPB concen
trations. Plasma drug levels were subjected to noncompart
mental analysis ( WinNonlin ver . 6.4 Certera Inc. , Princeton,
N.J. ) . The predicted steady -state levels > 500 ng /ml were
estimated using a twelve h dosing of 25 mg /kg dose of the
compound in mice.
Determination of Drug Concentration in Plasma

[ 0064 ] TPB was dissolved in DMSO at 1 mg/ml. Working
water from the stock solution . Standards (an eight-point
calibration curve ) and quality controls (at three levels) were
prepared by spiking the working standard solutions to blank
mouse plasma . One hundred ul aliquot of plasma was mixed
with 25 ul of internal standard spiking solution ( rilpivirine
1000 ng /ml in 50 % acetonitrile in water ), 1.5 ml ethyl
acetate was added and vortexed vigorously for 15 min . The
tubes were centrifuged at 1700xg for 5 min and 1.3 ml
supernatant was evaporated to dryness under a stream of
nitrogen at 40 ° C. The dried extract was reconstituted with
0.1 ml of 50 % acetonitrile in water and 5 ul was injected into
the LCMS /MS instrument. The dynamic range of the
method was 25-4000 ng /ml.
[ 0065 ] An Agilent 1200 HPLC system ( Agilent Technolo
gies , CA , USA ) coupled with AB Sciex API 3200 Q Trap
with an electrospray ionization source (Applied Biosystems,
Foster City, Calif., USA) was used . The mass transitions m / z
standard solutions were then prepared in 50 % methanol in

Viral Inhibition Test in Mice

[ 0066 ] Balb /C mice were obtained from the Jackson Labo
ratory (Bar Harbor, Me . , USA) . After acclimatization for

four days , groups of animals ( n = 6 per group ) were injected
intraperitoneally with 25 mg/kg body weight dose of TPB
diluted in saline or saline alone ( no drug control ). Following
three injections at 12 h intervals, 500 PFU of PRVABC59

virus diluted in PBS was inoculated into each mouse by the
subcutaneous ( SC ) route . Blood was collected by retro
orbital bleeding under anesthesia at days 2 , 3 , 4 , 5 , and 6

post - infection . Viral genome copies in the plasma were

determined by RT - PCR .

Statistical Analysis
[ 0067] Data were analyzed using GraphPad Prism soft
ware version 6.0 . Unpaired two - tailed Student's t -test for
pairwise comparison between the groups to determine sig
nificant differences in viral loads (RNA levels and infectious
titer) was performed . Data were represented as means
( SEM ).

Results

In Silico Screening of a Compound Library Against ZIKV

Polymerase (RdRp) Loops

[ 0068 ] Since the crystal structure of ZIKV RdRp was not
available when this project was initiated, we generated a
three - dimensional model of ZIKV RdRp through structural
modeling based on the analog of DENV - 3 RdRp structure
(PDB : 2J7U) . The choice of the DENV - 3 RdRP structure as
the template was due to its high level of protein sequence

homology ( 65 % identity and 78 % similarity ) and the high

resolution ( 1.8 D ) of the structure . The predicted ZIKV
RdRp structure superimposed closely with a recently solved
crystal structure ( see , e.g. , Duan et al . , 2017 EMBO J.
36 : 919-933 ) of ZIKV RdRp (FIG . 8 ) with C - alpha atom
RMSD of 2.519 . The target site appears to fit well and the
relative larger RMSD value should be mainly from the
flexible loops and the outer layers of the three domains . Like
RdRp structures in other flaviviruses, the ZIKV RdRp
structure model showed a very similar right-handed archi
tecture with fingers, palm and thumb subdomains ( FIG . 1A) .
Subsequently, we conducted in silico screening of a library
of 100,000 small molecule compounds against the catalytic
active site on the ZIKV RdRp molecule . The active site is in
the palm subdomain which is critical for de novo RNA
synthesis performed by ZIKV RdRp. Based on the in silico
screening data , the top 10 compounds with highest docking
scores are shown in Table 1. The molecular weights of these
compounds are also similar ( around 500 Da ) which are in the
appropriate range of druggable compounds.
Cell - Based Inhibition Test of the Lead Compounds Against
ZIKV Infection

2195.2 for internal standard were monitored . Chromato

[ 0069 ] Examination of PRVABC59 ZIKV growth in Vero
cells in the presence of 1 uM concentrations of the com
pounds ( cl - c10 ) showed that cl , 3 -chloro -N -[ ({ 4- [4- (2

0.5 ml/min . The retention times of analyte and internal
standard were 2 and 1.2 min respectively.

> 99 % in cells treated with TPB compared to the vehicle

541.2330.2 and 541.2212.2 for analyte and m / z 367 .

graphic separation was carried out on Phenomenex Synergi
Polar - RP ( 150x2.0 mm , 4u) column with isocratic mobile
phase consisting of 0.1 % formic acid in water ( A ) and 0.1 %
formic acid in acetonitrile ( B ) ( 20:80 v / v ) at a flow rate of

thienylcarbonyl)-1 -piperazinyl]phenyl} amino carbonoth
ioyl ]-1 -benzothiophene- 2-carboxamide ( TPB , FIG . 1B ) ,
exhibited the highest inhibitory activity among the 10 lead
compounds tested . While the ZIKV growth was inhibited ( as
determined by genome copies in the culture supernatants ) by
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only treated cells (FIG . 2A) , c . and c10 also inhibited virus
growth by nearly 70-80 % . Infectious virus yield was inhib

ited by at least 1000 - fold in the presence of 1 uM cl ( FIG .
2B ) whereas c6 and c10 inhibited the yield by nearly 10 - fold
at the same concentrations. Although the majority of the
compounds could be readily seen bound to the target site , cl ,
c6 , and c10 appeared to have made additional contacts with

the priming loop as well as other regions in the RdRp target
site ( FIG . 9 ) . From molecular docking analysis , it appears
that cl interacts with residues in the target site of the viral
RdRp ( FIG . 1C - D ) . Three hydrogen bonds of TPB are in

direct contact with two aspartic acid residues (D535 in motif
A and D665 in motif C) in RdRp ( FIG . 1C ) . Since these two
aspartic acid residues as well as D665 are highly conserved
residues in the target and active site of all RdRps of
flaviviruses and play critical roles in coordinating divalent

metal ions ( Mg ++ ) , TPB could potentially be a highly
promising anti-ZIKV as well as anti - flavivirus drug candi
date . So , from the initial cursory screening studies , TPB was
shown to inhibit ZIKV replication significantly .
[ 0070 ] We then tested the inhibitory activity of TPB in a

dose -dependent manner in the uM range. The results show
that even at 0.5 um concentration of TPB , significant
inhibitory activity against ZIKV replication was observed .

Both genome copy numbers ( FIG . 3A) and infectious virus
( FIG . 3B ) in the supernatants were reduced by over 100 - fold

at this concentration of TPB . Although TPB at 1 uM reduced
virus growth by over 1000 - fold, further increase in TPB

concentration did not result in further inhibition ( FIG .
3A - B ) . Viral E protein synthesis in infected cells was also
significantly inhibited at 0.5 UM TPB and was undetectable
at higher concentrations (FIG . 3C ) . These results suggest
that TPB is a potent inhibitor of ZIKV replication .
ZIKV Growth Inhibition of by TPB

[ 0071 ] Since we used the contemporary isolate of ZIKV
(PRVABC59, isolated from a patient in Puerto Rico in 2015 )

in our initial studies , we wanted to determine if TBP also has

antiviral activity against the historical isolate of the virus.

Our results suggest that the MR766 Ugandan isolate was

also sensitive to inhibition by TPB at the concentrations
tested ( FIG . 4A) . The extent of MR766 virus growth inhi
bition appeared to be similar to that of the PRVABC59 virus

( FIGS . 3 and 4A) . Overall, it appears that maximal ZIKV
growth inhibition by TPB could be achieved at 1 or 2 uM
concentrations and further increase had no significant inhibi
tory effect, indicating that the TPB inhibitory target is
saturable at these concentrations . In addition, not only TPB
inhibited ZIKV growth in Vero cells ( FIG . 3 ) , but also it
inhibited the virus growth in other cells such as human
trophoblast cell line HTR - 8 ( FIG . 4B ) as well as the human
testicular cell line NTERRA (FIG . 4C ) that are known to be
the targets of ZIKV infection in humans. Overall, these
studies suggest that TBP inhibits both the contemporary and
historical isolates of the virus and that the inhibition is not
cell- type dependent.
Characterization of TPB Antiviral Activity In Vitro : IC50

and CC50

[ 0072 ] Inhibitory Concentration 50 (IC50 ) Determination .
[ 0073 ] To characterize the anti - ZIKV potency of TPB , we
conducted studies to determine the inhibitory concentration
50 ( IC50) . We used serial 2 - fold dilutions of TPB and treated

the Vero cells infected with PRVABC59 . The culture super

natants were assayed for infectious virus by plaque assay
and expressed as % virus yield relative to the virus yield
without TPB . The data were statistically analyzed and the

IC50 concentration was determined to be about 94 nM (FIG .
5A) . The IC50 value of TPB in the 10-100 nM range also
suggests that TPB is a strong inhibitor of ZIKV and a
potential drug candidate for further development.
[ 0074 ] Cellular Cytotoxicity 50 (CC50) Determination .
[ 0075 ] Low level of cellular cytotoxicity is an essential
criterion for drug development. It also suggests whether the
drug's inhibitory effect is independent of cellular cytotox
icity due to the presence of the drug. Therefore, we con
ducted cell viability assay to determine the cellular cytotox
icity 50 ( CC50) concentration of TPB . Our results show that
CC50 of TPB is 19.4 UM (FIG . 5B ) . The selectivity index 50
( S150 , CC50/ IC50) is calculated to be 206. This high S150
also suggests that TBP is not only a potent inhibitor of ZIKV
at sub -micromolar concentrations but is also nontoxic to the
cells .
[ 0076 ] Comparison of TPB Inhibition with Other Known
Inhibitors of ZIKV.
[ 0077] To further compare the potency of TPB relative to
other identified ZIKV inhibitors, two inhibitors were exam
ined that have been recently shown to inhibit ZIKV repli
cation . Mycophenolic acid (MPA ) is an immunosuppressant
drug used to prevent rejection in organ transplantation and
was shown to inhibit DENV RNA replication ( see , e.g. ,

Diamond et al . , 2002 Virology 304 : 211-221 ) . In a screen of
FDA - approved drugs for inhibition of ZIKV infection , MPA
at 1 uM was found to inhibit infection of cells in vitro by
ZIKV by over 99 % ( see , e.g. , Barrows et al . , 2016 Cell Host
Microbe 20 : 259-270 ) . Likewise, Ivermectin (IVM) , an anti
parasitic drug was found to inhibit ZIKV infection strongly
at 10 uM ( see , e.g. , Barrows et al . , 2016 Cell Host Microbe
20 : 259-270 ) . A side- by - side comparison of the inhibitory
potency of TPB with MPA and IVM shows that while TPB
inhibited ZIKV yield by over 1000 - fold, MPA and IVM

inhibited virus yield by approximately 10- to 20 - fold ( FIG .
6 ) . These results suggest that TPB is more potent in inhib
iting ZIKV as compared to MPA or IVM .
Antiviral Activity of TPB In Vivo
[ 0078 ] Since TPB was found to be a potent inhibitor of
ZIKV replication in vitro , we wanted to examine if it also
inhibits virus replication and viremia in an immunocompe
tent mouse model. Therefore, a pharmacokinetics ( PK)
analysis of TPB in immunocompetent Balb / C mice was
conducted to examine the stability and in vivo retention of
the drug. The results of PK studies suggest that TPB is
retained in the mouse plasma at approximately 100 ng /ml
level 10-12 h post - injection at the two doses tested (FIG .
7A) . Based on non - compartment analysis of the data , it was
estimated that steady - state levels > 500 ng /ml of TPB ( ~ 1
UM) could be achieved using a twelve hour dosing at 25
mg/kg dose of the compound in mice . To examine the effect
of the drug on ZIKV growth in mice , groups of mice ( n = 6 )
were injected with the drug at 25 mg /kg dose and subse
quently infected with 500 PFU of ZIKV. Virus load in the
plasma of the animals at 24 hour intervals was determined .
Results of virus growth ( genome copies ) in individual
animals (FIG . 7B ) show that these immunocompetent mice
supported transient ZIKV growth and the level of viral RNA
detected on day 4 post - infection was nearly 40 - fold lower in
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mice injected with the drug as compared to the group
injected with the vehicle ( 5 % dextrose ) alone ( FIG . 7C ) . The
level of TPB in the plasma on average reached nearly 270
ng /ml by 2 days post- infection (FIG . 7D ) . Although this
level of TPB was not optimal for maximal virus growth
inhibition as observed under in vitro conditions, the results
suggest that TPB exerts significant growth inhibition of
ZIKV in vivo .

OTHER EMBODIMENTS

[ 0079 ] It is to be understood that while the invention has
been described in conjunction with the detailed description

thereof, the foregoing description is intended to illustrate
and not limit the scope of the invention , which is defined by
the scope of the appended claims . Other aspects , advantages,
and modifications are within the scope of the following
claims .

4. The method of claim 1 , wherein said non - nucleoside
RNA polymerase inhibitor is 3 - chloro - N - [{ {4-[4-( 2-thienyl

carbonyl)-1- piperazinyl]phenyl} amino ) carbonothioyl]-1
benzothiophene - 2 -carboxamide ( TPB ) .

5. The method of claim 1 , wherein said non - nucleoside

RNA polymerase inhibitor has an inhibitory concentration
50 (IC50 ) of from about 10 nM to about 200 nM .
6. The method of claim 1 , wherein said non -nucleoside

RNA polymerase inhibitor has a cytotoxicity concentration
50 (CC50 ) of from about 15 uM to about 25 uM .
7. The method of claim 1 , wherein said non -nucleoside

RNA polymerase inhibitor has a selective index 50 ( SI50 ) of
about 206 .

8. The method of claim 1 , wherein said administering step

is performed prior to said ZIKV infection or after said ZIKV
infection .

SEQUENCE LISTING
< 160 > NUMBER OF SEQ ID NOS : 3

< 210 > SEQ ID NO 1
< 211 > LENGTH : 17
< 212 > TYPE : DNA

< 213 > ORGANISM : Artificial Sequence

< 220 > FEATURE :

< 223 > OTHER INFORMATION : synthetic primer
< 400 > SEQUENCE : 1

ccgctgccca acacaag

17

< 210 > SEQ ID NO 2
< 211 > LENGTH : 24
< 212 > TYPE : DNA

< 213 > ORGANISM : Artificial Sequence
< 220 > FEATURE :

< 223 > OTHER INFORMATION : synthetic primer
< 400 > SEQUENCE : 2

ccactaacgt tcttttgcag acat

24

< 210 > SEQ ID NO 3
< 211 > LENGTH : 31
< 212 > TYPE : DNA

< 213 > ORGANISM : Artificial Sequence
< 220 > FEATURE :

< 223 > OTHER INFORMATION : synthetic probe
< 400 > SEQUENCE : 3

agcctacctt gacaagcaat cagacactca a

What is claimed is :

1. A method for treating a mammal having a Zika virus
( ZIKV ) infection , said method comprising: administering to
said mammal a composition comprising a non - nucleoside
RNA polymerase inhibitor.
2. The method of claim 1 , wherein said mammal is a
human .

3. The method of claim 1 , wherein said non -nucleoside

RNA polymerase inhibitor can bind to a catalytic active site
of an RNA -dependent RNA -polymerase ( RdRp ) of said
ZIKV to inhibit ZIKV replication .

31

9. The method of claim 1 , wherein said administering step
is performed prior to said ZIKV infection and after infection
said ZIKV infection .

10. The method of claim 1 , wherein said non - nucleoside

RNA polymerase inhibitor is administered intraperitoneally ,
intravenously, intramuscularly , or subcutaneously.
11. A method of preventing microcephaly in a fetus said
method comprising: administering a composition compris
ing a non - nucleoside RNA polymerase inhibitor to a mam

mal pregnant with said fetus, wherein said mammal has a
ZIKV infection .
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12. The method of claim 11 , wherein said mammal is a

human .

13. The method of claim 11 , wherein said non -nucleoside

RNA polymerase inhibitor is 3 -chloro -N -[({4-[4-(2 -thienyl
carbonyl)-1 -piperazinyl]phenyl }amino ) carbonothioyl]-1
benzothiophene-2 -carboxamide ( TPB ) .

14. A method of treating an adult mammal having Guil
to said mammal a composition comprising a non -nucleoside
RNA polymerase inhibitor, wherein said mammal has a
lain - Barre syndrome said method comprising: administering

ZIKV infection .
15. The method of claim 14 , wherein said mammal is a

human .

16. The method of claim 14 , wherein said non - nucleoside

RNA polymerase inhibitor is 3 -chloro -N -[({4-[4-(2- thienyl

carbonyl)-1-piperazinyl]phenyl} amino )carbonothioyl]-1
benzothiophene - 2 -carboxamide ( TPB ) .

